• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

专利制度目标的背离:如何弥补生物技术专利的状况

Alienation from the Objectives of the Patent System: How to Remedy the Situation of Biotechnology Patent.

机构信息

Kenneth Wang School of Law, Soochow University, Suzhou, People's Republic of China.

出版信息

Sci Eng Ethics. 2019 Jun;25(3):791-811. doi: 10.1007/s11948-018-0043-3. Epub 2018 Mar 12.

DOI:10.1007/s11948-018-0043-3
PMID:29532279
Abstract

Some fundamental biotechnologies hold unprecedented potential to eradicate many incurable diseases. However, in absence of regulations, the power of patent makes the future use of some important biotechnology in few institution's hands. The excessive patents restrict researcher access to the fundamental technologies. It generates concerns and complaints of deteriorating the public health and social welfare. Furthermore, intellectual curiosities, funding, respect among colleagues etc., rather than patents, are the real motivations driving a major ground-breaking discoveries in biotechnology. These phenomena reveal that some biotechnology patents are alienated from the purpose of patent system. Therefore, it is necessary to take some approaches to stop over-patenting these fundamental biotechnology inventions. This article proposes a model regulatory framework for controlling biotechnology patent alienating from the purpose of patent system.

摘要

一些基础生物技术拥有根除许多不治之症的前所未有的潜力。然而,在缺乏监管的情况下,专利的力量使得一些重要生物技术的未来应用掌握在少数机构手中。过多的专利限制了研究人员获得基础技术的机会。这引发了人们对公共卫生和社会福利恶化的担忧和抱怨。此外,推动生物技术重大突破性发现的真正动力是好奇心、资金、同事之间的尊重等,而不是专利。这些现象表明,一些生物技术专利已经偏离了专利制度的目的。因此,有必要采取一些措施来阻止对这些基础生物技术发明的过度专利保护。本文提出了一个控制偏离专利制度目的的生物技术专利的监管框架模型。

相似文献

1
Alienation from the Objectives of the Patent System: How to Remedy the Situation of Biotechnology Patent.专利制度目标的背离:如何弥补生物技术专利的状况
Sci Eng Ethics. 2019 Jun;25(3):791-811. doi: 10.1007/s11948-018-0043-3. Epub 2018 Mar 12.
2
Patents: patenting of stem cell related inventions in Europe.专利:欧洲干细胞相关发明的专利申请情况
Biotechnol J. 2006 Apr;1(4):384-7. doi: 10.1002/biot.200600021.
3
Patent first, ask questions later: morality and biotechnology in patent law.先申请专利,后提出问题:专利法中的道德与生物技术
William Mary Law Rev. 2003 Dec;45(2):469-547.
4
Patenting pieces of people.为人体部位申请专利。
Nat Biotechnol. 2003 Apr;21(4):341. doi: 10.1038/nbt0403-341.
5
Innovations and intellectual property: the case of genomic patenting.创新与知识产权:基因专利案例
J Policy Anal Manage. 2003 Winter;22(1):5-25. doi: 10.1002/pam.10093.
6
Biotechnology patenting policy in the European Union--as exemplified by the development in Germany.欧盟的生物技术专利政策——以德国的发展为例。
Adv Biochem Eng Biotechnol. 2007;107:13-39. doi: 10.1007/10_2007_049.
7
Ethico-legal issues in biomedicine patenting: a patent professional viewpoint.生物医学专利中的伦理法律问题:专利专业人士视角
Sci Eng Ethics. 2005 Jan;11(1):117-36. doi: 10.1007/s11948-005-0064-6.
8
Patent prosecution strategies for biotechnological inventions.生物技术发明的专利申请策略。
Assay Drug Dev Technol. 2004 Dec;2(6):697-702. doi: 10.1089/adt.2004.2.697.
9
Patents, biomedical research, and treatments: examining concerns, canvassing solutions.专利、生物医学研究与治疗:审视关切,探寻解决方案
Hastings Cent Rep. 2007 Jan-Feb;37(1):S1-36. doi: 10.1353/hcr.2007.0006.
10
EPO neem patent revocation revives biopiracy debate.EPO对印楝专利的撤销引发了生物剽窃辩论。
Nat Biotechnol. 2005 May;23(5):511-2. doi: 10.1038/nbt0505-511.

本文引用的文献

1
Trials of embryonic stem cells to launch in China.中国将开展胚胎干细胞试验。
Nature. 2017 May 31;546(7656):15-16. doi: 10.1038/546015a.
2
CRISPR: Pursuit of profit poisons collaboration.CRISPR:对利润的追逐毒害了合作。
Nature. 2016 Apr 14;532(7598):172-3. doi: 10.1038/532172a.
3
DuPont in CRISPR-Cas patent land grab.杜邦卷入CRISPR-Cas专利争夺。
Nat Biotechnol. 2016 Jan;34(1):13. doi: 10.1038/nbt0116-13.
4
Gene patents, patenting life and the impact of court rulings on US stem cell patents and research.基因专利、生命专利以及法院裁决对美国干细胞专利和研究的影响。
Regen Med. 2014 Mar;9(2):191-200. doi: 10.2217/rme.13.93.
5
AMP v Myriad: the Supreme Court gives a win to personalized medicine.AMP 诉迈里亚德案:最高法院支持个性化医疗
J Mol Diagn. 2013 Nov;15(6):731-2. doi: 10.1016/j.jmoldx.2013.09.002.
6
Myriad Genetics: In the eye of the policy storm.迈锐德遗传公司:政策风暴眼中的焦点。
Genet Med. 2010 Apr;12(4 Suppl):S39-70. doi: 10.1097/GIM.0b013e3181d72661.
7
Are patents impeding medical care and innovation?专利是否阻碍了医疗保健和创新?
PLoS Med. 2010 Jan;7(1):e1000208. doi: 10.1371/journal.pmed.1000208. Epub 2010 Jan 5.
8
Trips and public health: solutions for ensuring global access to essential AIDS medication in the wake of the Paragraph 6 Waiver.贸易相关知识产权协定与公共卫生:在第6段豁免之后确保全球获取基本艾滋病药物的解决方案
J Contemp Health Law Policy. 2008 Fall;25(1):142-65.
9
RNA interference (RNAi) patents and human health related applications of RNAi.RNA干扰(RNAi)专利以及RNA干扰与人类健康相关的应用。
Recent Pat DNA Gene Seq. 2007;1(2):128-33. doi: 10.2174/187221507780887036.
10
Negotiating the RNAi patent thicket.应对RNA干扰专利丛林。
Nat Biotechnol. 2007 Mar;25(3):273-5. doi: 10.1038/nbt0307-273. Epub 2007 Mar 1.